SALT LAKE CITY, Nov. 5, 2025 — Recursion (Nasdaq: RXRX) announced it has reached a $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells, the second neuro map designed to accelerate treatments for neurological diseases.
The clinical stage TechBio company decoding biology to radically improve lives said with this achievement, it will have reached over $500 million in milestone and upfront payments across all its partnerships and collaborations.
As of October 9, 2025, Recursion had approximately $785 million of cash and cash equivalents (unaudited). Based on current operating plans and with no additional financing, the Company’s expected cash runway extends through the end of 2027.
Recursion announced progress in its ELUCIDATE Phase 1/2 trial evaluating REC-617, a precision-designed oral CDK7 inhibitor. The monotherapy dose-escalation study established the maximum tolerated dose (MTD) at 10 mg once-daily, demonstrating a manageable safety profile and preliminary anti-tumor activity consistent with the December 2024 update.
Recursion also announced progress on REC-7735, with nomination as a Development Candidate and IND-enabling studies now underway. REC-7735 is a precision-designed PI3K⍺ H1047R inhibitor generated using the Recursion OS. In preclinical studies, REC-7735 demonstrated significant tumor regressions at low doses, outperforming approved agents, while maintaining high selectivity (>100-fold) over wild-type PI3K⍺ to reduce the risk of dose-limiting hyperglycemia.
Contact:
Media Contact
media@recursion.com
Investor Contact
investor@recursion.com
Source: Recursion Pharmaceuticals
